biotechnologies Amgen Inc. is in a pitched battle with the Internal Revenue Service over the company’s international tax strategy and $10.7 billion in back taxes and penalties that the agency says are owed to it. due.
IRS says Amgen underreported taxable income by nearly $24 billion from 2010 to 2015 by improperly allocating what the agency says should have been U.S. profits to a Puerto Rico subsidiary who oversees the manufacture of the company’s drugs.
wsj
Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
